Sebastian Newrzela

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC.

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC.

Journal: Nature
Published: November 06, 2024

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

Journal: Blood
Published: January 12, 2022

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Journal: Leukemia
Published: October 24, 2020

SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.

SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.

Journal: Haematologica
Published: February 05, 2020

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Journal: Blood
Published: September 26, 2019

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Journal: Leukemia
Published: July 30, 2019

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Journal: Oncotarget
Published: September 06, 2017

Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.

Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.

Journal: Oncotarget
Published: March 13, 2017

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Journal: Nature communications
Published: December 28, 2016

Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology.

Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology.

Journal: Leukemia & lymphoma
Published: September 20, 2016

Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other.

Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other.

Journal: PloS one
Published: August 31, 2016

A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.

A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.

Journal: Oncotarget
Published: July 22, 2016
Showing 1-12 of 27

Last Updated: 09/26/2026